Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decrease in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTGet Free Report) was the recipient of a large decline in short interest in February. As of February 28th, there was short interest totalling 42,300 shares, a decline of 23.8% from the February 13th total of 55,500 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily volume of 63,400 shares, the short-interest ratio is presently 0.7 days.

Lixte Biotechnology Price Performance

NASDAQ LIXT traded up $0.02 on Monday, hitting $1.23. 7,139 shares of the stock were exchanged, compared to its average volume of 317,640. Lixte Biotechnology has a 52-week low of $1.02 and a 52-week high of $4.40. The company has a market capitalization of $2.77 million, a price-to-earnings ratio of -0.71 and a beta of 0.19. The company’s 50-day moving average price is $1.92 and its two-hundred day moving average price is $1.91.

Hedge Funds Weigh In On Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. Atlas Legacy Advisors LLC purchased a new stake in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTFree Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned approximately 0.56% of Lixte Biotechnology as of its most recent SEC filing. Institutional investors and hedge funds own 5.10% of the company’s stock.

About Lixte Biotechnology

(Get Free Report)

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.

Featured Articles

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.